UBS Group
AAPG

UBS Group’s Ascentage Pharma AAPG Stock Holding History

UBS Group’s Portfolio AAPG Stock Details AAPG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.96K Sell
124
-4,108
-97% -$101K ﹤0.01% 9169
2025
Q4 		$111K Sell
4,232
-14,113
-77% -$462K ﹤0.01% 6862
2025
Q3 		$716K Buy
18,345
+10,988
+149% +$445K ﹤0.01% 5827
2025
Q2 		$290K Buy
7,357
+4,879
+197% +$129K ﹤0.01% 6463
2025
Q1 		$54.4K Buy
+2,478
New +$47K ﹤0.01% 7528

Other funds holding AAPG

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
XC
XY Capital Central, Hong Kong $101M AUM 1.14% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return

UBS Group's AAPG Position: Q1 2026 in Review

UBS Group reduced its Ascentage Pharma (AAPG) stake by 97% in Q1 2026, selling an estimated $101K and leaving 124 shares worth $2.96K. The position accounts for ﹤0.01% of the portfolio, ranked #9169.

UBS Group first reported a position in AAPG in Q1 2025 and has held it in 5 quarters since. The position peaked at $716K in Q3 2025. 7 funds tracked by Wall St. Rank hold AAPG as of Q1 2026.

  • UBS Group held 124 shares of Ascentage Pharma worth $2.96K as of Q1 2026.
  • UBS Group sold 4,108 Ascentage Pharma shares in Q1 2026, an estimated $101K.
  • Ascentage Pharma made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9169 holding.
  • UBS Group first reported a position in Ascentage Pharma in Q1 2025 and has held it in 5 quarters since.
  • UBS Group's Ascentage Pharma position peaked at $716K in Q3 2025.
  • 7 funds tracked by Wall St. Rank held Ascentage Pharma as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.